by Richard Daverman, PhD
August 20, 2012 -- The Chengdu Institute of Biological Products (CDIBP) has licensed technology for producing less-expensive conjugate vaccines from Fina Biosolutions LLC, a Maryland company that provides protein purification and bioconjugation services. CDIBP will use the technology to develop pneumococcal conjugate vaccines for the China market. CDIBP is a subsidiary of China National Biotec Group (CNBG), which is part of China National Pharmaceutical Group Corporation (Sinopharm). CDIPB will pay FinaBio an upfront fee, milestone payments and royalties. More details....
